nCounter®
PanCancer Pathways Panel

Helping Your Research

Gene expression profiling can be challenging because reproducibility and data analysis can be extremely demanding. The nCounter PanCancer Pathways Panel offers fast and high-throughput multiplex gene expression analysis solution for human or mouse genes. Each panel comes with 770 genes from 13 cancer-associated canonical pathways to support the understanding of basic cancer biology:

  • Measure treatment effects on pathways 
  • Score pathway deregulation with end-to-end analysis 
  • Generate follow-up research hypothesis using pathway visualizations 
  • Rapidly and easily screen samples for biomarker discovery or drug mechanism of action studies

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

How It Works

The nCounter PanCancer Pathways Panel come with simple workflow of less than 15 minutes hands-on time and streamlined analysis for data in under 24 hours.

*All nCounter Panel products are provided as a CodeSet product sold in increments of 12 reactions. Master kits, reagents and cartridges are also required and sold separately.

01:

Highly multiplexed analysis of basic cancer biology and pathway deregulation activity 

02:

Measure gene expression with 770 genes representing all major cancer pathways including: Wnt, Hedgehog, apoptosis, cell cycle, RAS, PI3K, STAT, MAPK, Notch, TGF-β, chromatin modification, transcriptional regulation, and DNA damage control

03:

Customizable with up to 55 additional user-defined genes with Panel Plus option 

In The Lab

Hallmarks of Cancer Supplement

Read More
Hallmarks of Cancer

Panel Selection Tool

Find the gene expression panel for your research with Panel Pro

Find Your Panel

Product Information

Specifications
Signature/Pathways
Catalog Information
Product Comparison
Catalog Information
Specifications
Signature/Pathways

Pathway Gene Coverage

Below are brief descriptions of the Pathways included in the PanCancer Pathways Panel. Please click on the name of the pathway to view more information, including detailed information on pathway genes and KEGG pathway gene maps

Catalog Information
Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Catalog Information

Related Resources

See All Resources
Product Bulletin Hallmarks of Cancer – Product Bulletin
Hallmarks of Cancer: New Dimensions
Whitepaper PanCancer-Pathways – Whitepaper
Whitepaper PanCancer Pathways nSolver Analysis Module – Whitepaper
Manual/Instructions NanoU Training Videos

Publications

View All Publications

Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer

BACKGROUND: Tertiary Lymphoid Structures (TLS) correlate with positive outcomes in patients with NSCLC and the efficacy of immune checkpoint blockade (ICB) in cancer. The actin regulatory protein hMENA undergoes tissue-specific splicing, producing the epithelial hMENA(11a) linked to favorable prognosis in early NSCLC, and the mesenchymal hMENADeltav6 found in invasive cancer cells and pro-tumoral cancer-associated fibroblasts (CAFs).

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

BACKGROUND: HER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance in part due to HER2 heterogeneity (HET) is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) and pertuzumab (T-DM1+P) clinical trial in early-stage HER2-positive breast cancer, none of the patients with HER2-HET tumors had pathologic complete response (pCR).

Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology

Posterior fossa type A (PF-EPN-A, PFA) ependymoma are aggressive tumors that mainly affect children and have a poor prognosis. Histopathology shows significant intratumoral heterogeneity, ranging from loose tissue to often sharply demarcated, extremely cell-dense tumor areas.

Request a Quote

Contact our helpful experts and we’ll be in touch soon.